IRhythm's Zio ECG System Gets Approval in Japan, Stock Falls
Morocco Reports First Mpox Case Amid Ongoing Global Outbreak
PacBio's Stock Up on Munster Deal for Male Infertility Research
Baird Adjusts Price Target on Quest Diagnostics to $155 From $154, Maintains Neutral
Quest Diagnostics(DGX.US) Officer Sells US$5.04 Million in Common Stock
Should Value Investors Buy Quest Diagnostics (DGX) Stock?
Form 144 | Quest Diagnostics(DGX.US) Officer Proposes to Sell 5.04 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Aug 29, $Quest Diagnostics(DGX.US)$ Officer PREVOZNIK MICHAEL E intends to sell 32,551 shares of its common stock on Aug 29, with a total market value of approximately $5.04
Quest Diagnostics to Speak at the Morgan Stanley 22nd Annual Global Healthcare Conference
Express News | Quest Diagnostics Inc : Evercore ISI Resumes Coverage With in Line Rating; Target Price $165
Investing in Quest Diagnostics (NYSE:DGX) Five Years Ago Would Have Delivered You a 66% Gain
Evercore Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $165
Quest Diagnostics: Hold Rating Affirmed Amid Balanced Risk/Reward Profile and Premium Valuation
Analysts Conflicted on These Healthcare Names: Quest Diagnostics (DGX), Astrana Health (ASTH) and Dexcom (DXCM)
Quest Diagnostics Analyst Ratings
Quest Diagnostics Expands in North America With New Acquisition
AI-First Approach to Cancer Diagnostics Earns Ibex Medical Analytics Notable Milestones
Cleveland Diagnostics' Prostate Cancer Awareness Campaign 'A PSA on PSA' Returns This September
Quest Diagnostics Stock: Is Wall Street Bullish or Bearish?
Barclays Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $154
Barclays Remains a Hold on Quest Diagnostics (DGX)
No Data
No Data